GlyCylic Salicylic Acid 17 g/100mL Liquid
by The Tetra Corporation · 1 BOTTLE in 1 BOX (49406-009-15) / 15 mL in 1 BOTTLE
NDC 49406-0009-15
🏷️ FDA NDC (as labeled)
49406-009-15
billing pads the product segment with a zero
OTC
On market
Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
🆔 Identity & classification
FDA NDC (as labeled)
49406-009-15
Product NDC
49406-009
11-digit billing NDC
49406000915
UNII
O414PZ4LPZ
Application #
M005
SPL Set ID
501d3ba9-ba42-4c1c-983b-492adaee039d
DEA schedule
Non-controlled
Marketing category
OTC MONOGRAPH DRUG
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2022-07-01
Route
TOPICAL
Dosage form
LIQUID
Substance
SALICYLIC ACID
Why two NDCs?
The FDA registers this code as 49406-009-15 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 49406-0009-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️ RxNorm drug class
This medicine belongs to the Salicylic acid and derivatives class.
Drug family (ATC)
Salicylic acid and derivatives, Other antifungals for topical use, Antiinflammatory agents, non-steroids
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
🏭 Manufacturer & labeler
LabelerThe Tetra Corporation
FDA applicationM005 (OTC MONOGRAPH DRUG)
Labeler code49406
First marketedJul 2022
Product typeHuman Otc Drug
Portfolio5 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
📖 What it is MedlinePlus · NLM
Topical salicylic acid is used to help clear and prevent pimples and skin blemishes in people who have acne. Topical salicylic acid is also used to treat skin conditions that involve scaling or overgrowth of skin cells such as psoriasis (a skin disease in which red, scaly patches form on some areas of the body), ichthyoses (inborn conditions that cause skin dryness and scaling), dandruff, corns, calluses, and warts on the hands or feet. Topical salicylic acid should not be used to treat genital warts, warts on the face, warts with hair growing from them, warts in the nose or mouth, moles, or b...
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- It's designed to treat acne. Salicylic acid helps by loosening and removing dead skin cells that clog pores — the buildup that leads to breakouts. The multi-step system on this lab...
- What is this salicylic acid product actually supposed to do for my skin?
- Some mild tingling, stinging, and peeling is actually expected — that's the salicylic acid doing its job by clearing away dead skin cells. But if the burning or peeling feels exces...
- My skin feels like it's burning and peeling. Is that normal?
Patient education
Supplement & herbal interactions
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Salicylic Acid?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3K9958V90M
A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
-
UNII A1A1I8X02B
A clear liquid solvent derived from ethylene glycol. It helps dissolve active ingredients and improve how the medicine flows and mixes in liquid formulations.
-
UNII 03O98E01OB
Ethyl pyruvate is a small organic compound derived from pyruvic acid. It acts as a solvent and preservative in medications, helping dissolve other ingredients and extend shelf life.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 0WT12SX38S
Glycolic acid is an alpha-hydroxy acid derived from sugar cane that helps dissolve and remove dead skin cells. In topical medicines, it works as an exfoliant and pH adjuster to improve skin penetration and product effectiveness.
-
UNII 9679TC07X4
Iodine is a chemical element used in medicines as an antiseptic and preservative. It helps prevent bacterial and fungal growth, keeping the product safe and stable during storage.
-
UNII KYR8BR2X6O
Pyroxylin is a cellulose derivative made by treating plant fibers with nitric acid. It serves as a film-former and binder in medications, helping create coatings on tablets and capsules or holding ingredients together in solid dosage forms.
7 inactive ingredients listed in the exact product block matched to this NDC.
The official label also statesCollodion USP, SDA-40-B 200pf, Glycerin USP, Ethoxydiglycol (Transcutol/Carbitol), Glycolic Acid 70%, Ethyl Pyruvate, Povidone/Iodine USP
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Salicylic Acid .17 g/7g 00363-0219-25 | Walgreen | 7 g | — | — | FDA listed | — |
| Compound W Total Care Wart and Skin Kit 49354-0130-00 | HK | 1 kit | — | — | FDA listed | — |
| GlyCylic 17 g/100mLthis 49406-0009-15 | The | 1 bottle | — | — | FDA listed | — |
| Compound W 170 mg/g 51142-0595-12 | ASO | 1 tube | — | — | FDA listed | — |
| Veraciti 17 g/100g 54633-0115-15 | The | 15 g | — | — | FDA listed | — |
| Wart Remover Gel .17 g/g 56104-0237-07 | Premier | 7 g | — | — | FDA listed | — |
| Compound W 170 mg/g 63029-0595-12 | Medtech | 1 tube | — | — | FDA listed | — |
| Goodnites Wart Removal Gel .17 g/mL 85578-0005-01 | Zhengzhou | 20 ml | — | — | FDA listed | — |
| BPLXKUR Wart Remover 17 g/100mL 85578-0008-01 | Zhengzhou | 1 bottle | — | — | FDA listed | — |
| Kingskin Saca Callos 17 g/100mL 55758-0442-15 | Pharmadel | 1 bottle | — | — | FDA listed | — |
| Goodnites Wart Remover 17 g/100mL 85578-0001-01 | Zhengzhou | 1 bottle | — | — | FDA listed | — |
| Wart Remover 17 g/100mL 10095-0505-06 | World | 1 bottle | — | — | FDA listed | — |
| BEHATMH 17% Salicylic acid Wart Remover Serum Pen 17 g/100mL 85304-0015-01 | Guangzhou | 3 bottles | — | — | FDA listed | — |
| TACRUITF 17% Salicylic acid Wart Remover Serum 17 g/100mL 85304-0010-01 | Guangzhou | 2 bottles | — | — | FDA listed | — |
| Kingskin 17 g/100mL 55758-0409-15 | Pharmadel | 1 bottle | — | — | FDA listed | — |
| Wart Remover-SALICYLIC ACID 17 g/100mL 87295-0001-01 | Ecommerce | 1 bottle | — | — | Discontinued | — |
| Pureskin wart remover 17 g/100mL 87217-0002-01 | BENLONG | 1 bottle | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2022
On the market since
Jul 2022
📍
2026
Currently FDA-listed
4 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Salicylic Acid (matched by generic name) — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Salicylic Acid. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$11.2K
Claims incl. refills
43
Beneficiaries
35
Spend / beneficiary
$319.01
Spend / claim
$259.66
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for GlyCylic (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 37%
Female · 63%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 49406-0009-15 You're viewing this | 1 BOTTLE in 1 BOX (49406-009-15) / 15 mL in 1 BOTTLE | 2022-07-01 | Active |
🧭 About this NDC listing & data coverage
Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 49406-009-15, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 49406-0009-15, written without dashes as 49406000915. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 49406-0009-15, the first segment (49406) is the labeler code FDA assigned to The Tetra Corporation; the middle segment (0009) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (15) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by The Tetra Corporation. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
The Tetra Corporation is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
🎯 Indications and Usage ▾
Uses for the removal of common and plantar warts. The common wart is easily recognized by the rough 'cauliflower-like' appearance of the surface. The plantar wart exists only on the bottom of the foot and interrupts footprint pattern.
⏱️ Dosage and Administration ▾
Directions • wash affected area, may soak wart in warm water for 5 minutes • dry area thoroughly • apply small amount of wart remover with applicator to sufficiently cover each wart • let dry and repeat this procedure once or twice daily until wart is removed for up to 12 weeks
⚠️ Warnings ▾
Warnings FOR EXTERNAL USE ONLY. Flammable • keep away from fire or flame. • cap bottle tightly and store at room temperature away from heat. Do not use • if you are a diabetic or have poor blood circulation, except under the advice and supervision of a doctor or podiatrist. • irritated, infected or reddened skin. • genital warts and warts on the face. • moles, birthmarks and warts with hair growing from them. • mucous membranes.
When using this product • avoid contact with eyes. If product gets into the eyes, flush with water for 15 minutes. • avoid inhaling vapors. Stop use and ask doctor if • discomfort persists.
🧪 Active Ingredient ▾
Active Ingredient Salicylic Acid 17%
🧪 Inactive Ingredients ▾
Inactive ingredients Collodion USP, SDA-40-B 200pf, Glycerin USP, Ethoxydiglycol (Transcutol/Carbitol), Glycolic Acid 70%, Ethyl Pyruvate, Povidone/Iodine USP
🎯 Purpose ▾
Purpose Wart Remover
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.